Company intelligence / Profile preview

Shinhan Venture Investment

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Shinhan Venture Investment is not itself a drug developer, but invests in companies ranging from early drug discovery (preclinical) to later clinical development. Its portfolio includes companies developing molecular glues, PROTACs, and AI-driven healthcare solutions, with some portfolio companies reporting preclinical or early clinical results[2].

Therapeutic areas: OncologyNeurologyOther
Modalities: AntibodySmall moleculeMolecular glue therapyPROTAC therapyArtificial intelligence-based drug development
Industry: Investors

Partnerships

Global Brain Corporation (for fund management)[7]

Beyond the preview

Go deeper on Shinhan Venture Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shinhan Venture Investment.

Explore the full profile